nuclear receptor coactivator 5Genealiases: CIA · bA465L10.6
Q-omics provides the consensus-scored NCOA5 profile across patient tissues and cancer cell-line models. NCOA5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NCOA5 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, NCOA5 protein abundance shows 25,295 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, THCA, and GBM as cancer lineages where NCOA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCOA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCOA5 survival associations across molecular data types. NCOA5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCOA5 RNA expression–survival associations across cancer types. High NCOA5 expression shows unfavorable associations in LIHC, but favorable associations in KIRC, HNSC, PAAD, LUSC and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NCOA5 RNA expression.
This table summarizes NCOA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NCOA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCOA5 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, STAD, COAD and KIRC. The THCA box plot shows higher NCOA5 RNA expression in normal versus tumor tissue (log2 FC = −1.113, t-test p < 0.001).
This table shows molecular features associated with NCOA5 in patient tissues and cancer cell lines. In patient samples, NCOA5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NCOA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
